210. Exits: $10.8B Exit to Merck with Prometheus Biosciences CEO Mark McKenna

This podcast is for informational and educational purposes only and does not constitute financial, investment, legal, or medical advice. The views and opinions expressed by hosts and guests are their own and do not necessarily reflect those of State of MedTech LLC. Nothing discussed on this podcast should be interpreted as a recommendation to buy, sell, or hold any investment or security. Listeners should conduct their own due diligence and consult with a qualified financial advisor, attorney, or other professional before making any financial or investment decisions.00:00 Introduction and Welcome00:32 Guest Introduction: Mark McKenna00:42 The Prometheus Acquisition by Merck01:01 Mark's Career Journey and Decision to Join Prometheus04:55 Challenges and Strategies in the First Year06:48 Key Inflection Points and Fundraising08:58 Building a Competitive and Sustainable Company13:32 Navigating Market Challenges and Competition19:33 Reflections and Leadership Insights21:32 Future of Biotech and Industry Concerns24:42 Conclusion and FarewellFor limited time only - Get the Medical Sales Network Effects Program for 60% off https://salesnetworkeffectsprogram.mykajabi.com/offers/FV2MG8sK?coupon_code=PODCAST2024Follow The State of MedTech on:⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠TikTok⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠Follow Omar M. Khateeb on⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠TikTok⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠